Substance / Medication

Moexipril

Overview

Active Ingredient
moexipril
RxNorm CUI
30131

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Comparative study between univariate spectrophotometry and multivariate calibration as analytical tools for simultaneous quantitation of Moexipril and Hydrochlorothiazide.
Tawakkol Shereen M, Farouk M, Elaziz Omar Abd et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2014
PMID: 24954754Observational
Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
Charatcharoenwitthaya Phunchai, Talwalkar Jayant A, Angulo Paul et al. · Dig Dis Sci · 2010
PMID: 19255851Observational
[The use of moexipril in postmenopausal women with hypertension and associated changes of bone mineral density].
Kirichenko A A, Demel'khanova T S, Riazantsev A A et al. · Kardiologiia · 2005
PMID: 16091658Observational
[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure].
Tepliakov A T, Pchel'nikov A V, Garganeeva A A et al. · Klin Med (Mosk) · 2005
PMID: 15759492Observational
Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension.
Asmar Roland, Sayegh Fady, Tracz Wiesława et al. · Acta Cardiol · 2002
PMID: 11918132Observational
Structural identification of degradants of moexipril by LC-MS/MS.
Challa Purushotham Reddy, K Ramakrishna, K M V Narayana Rao · Biomed Chromatogr · 2017
PMID: 28493358Other
Electrochemistry of moexipril: experimental and computational approach and voltammetric determination.
Taşdemir Hüdai I, Kiliç E · Pharmazie · 2014
PMID: 25272934Other
Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron Ryan T, Coleman Ryan G, Day Jon P et al. · Biochem Pharmacol · 2013
PMID: 23473803OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Moexipril (substance)
SNOMED CT
373442003
UMLS CUI
C0066685
RxNorm CUI
30131

Clinical Data

This intervention maps to 10 entities in the Healos knowledge graph.

3
Conditions
4
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.